KLRS 10-Q: SEC filing
Kalaris Therapeutics
Filed with the SEC on · accession 0001193125-26-455378
KLRS filed a 10-Q (quarterly report) with the SEC on Nov 10, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved -18.7% by the first close after the filing.
Summary of the filing
Kalaris Therapeutics filed its quarterly 10-Q report for the period ending September 30, 2026, disclosing routine financial statements, equity activity, and related-party transactions.
Key details
How KLRS stock reacted
Close before
$2.30
Nov 9, 2026
First close after
-18.70%
$1.87
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for KLRS, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for KLRS?
Click hereFrequently asked questions
What did KLRS file with the SEC on Nov 10, 2026?
KLRS filed a 10-Q (SEC filing). Kalaris Therapeutics filed its quarterly 10-Q report for the period ending September 30, 2026, disclosing routine financial statements, equity activity, and related-party transactions.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
How did KLRS stock react to this filing?
KLRS closed at $2.30 before the filing and $1.87 on Nov 10, 2026 (-18.70%).
Other KLRS SEC filings
Get alerts when KLRS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days